NCT02934568Active, not recruitingPhase 2
Ribociclib (LEE011) Rollover Study for Continued Access
An Open-label, Multi-center Rollover Protocol for Patients Who Have Participated in a Novartis-sponsored Ribociclib (LEE011) Study and Are Continuing to Benefit From Ribociclib as Single Agent or in Combination With Other Investigational Treatments
Source: ClinicalTrials.gov · Last updated 16 Apr 2026
Brief summary (registry, in English)
This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary objective(s) or has been halted for other reasons.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- First submitted
- 10 Oct 2016
- Start date
- 15 Dec 2016
- Primary completion date
- 1 Feb 2027
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Childhood cancers
- NCT number
- NCT02934568
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 22
- From 15 Dec 2016 to the primary completion date, 1 Feb 2027
- 12 sites in 6 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patient has been permanently discontinued from ribociclib (LEE011) in the parent protocol for any reason.
- Patients who do not meet parent protocol criteria to continue study treatment.
Who the study is looking for
- Patient is currently enrolled in an eligible Novartis-sponsored study and receiving ribociclib (LEE011) as single agent or in combination with other investigational treatment.
- Patient is currently deriving clinical benefit from the study treatment, as determined by the investigator.
Age in the registry: 0 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (12)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Cologne | Germany | Unknown status |
| - Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Lyon | France | Unknown status |
| - Coordinator of this site? Confirm its status | Villejuif | France | Unknown status |
| - Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
| - Coordinator of this site? Confirm its status | Tainan | Taiwan | Unknown status |
| - Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
| The Regents of the Uni of Michigan Coordinator of this site? Confirm its status | Ann Arbor | United States | Unknown status |
| University of Alabama at Birmingham Coordinator of this site? Confirm its status | Birmingham | United States | Unknown status |
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| Broome Oncology Coordinator of this site? Confirm its status | Johnson City | United States | Unknown status |
| St Jude Childrens Research Hospital Coordinator of this site? Confirm its status | Memphis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.